What is Telomir Pharmaceuticals, Inc. Common Stock (TELO) stock price today?

Telomir Pharmaceuticals, Inc. Common Stock (TELO) currently trades at $1.40 per share. The stock has a market capitalization of $99.72M and a P/E ratio of —x.

Is TELO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Telomir Pharmaceuticals, Inc. Common Stock has a Smart Value Score of 16/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is —.

Is Telomir Pharmaceuticals, Inc. Common Stock financially healthy?

Telomir Pharmaceuticals, Inc. Common Stock's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of — places it in the —.

TELO

Telomir Pharmaceuticals, Inc. Common Stock

NASDAQ: TELO · HEALTHCARE · BIOTECHNOLOGY

$1.40

-3.45% today

Updated 2026-04-30

Market cap

$99.72M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.33

Dividend yield

—

52W range

$1 – $3

Volume

0.1M

Market cap

$99.72M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.33

Dividend yield

—

52W range

$1 – $3

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.3

Quality

B+

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$15.50

+1007.14%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-1.20M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-854147.00	$-13.07M	$-16.53M	$-10.41M	$-2.06M
EPS	—	—	—	—	$-0.33
Free cash flow	$-468661.00	$-3.86M	$-5.07M	$-3.69M	$-1.20M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
TELO	$99.72M	16	4.3	3.0	5.0	7.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Telomir Pharmaceuticals, Inc. Common Stock trades at $1.40. Our Smart Value Score of 16/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Telomir Pharmaceuticals, Inc. Common Stock's stock price?

Telomir Pharmaceuticals, Inc. Common Stock (TELO) trades at $1.40.

Is Telomir Pharmaceuticals, Inc. Common Stock overvalued?

Smart Value Score 16/100 (Grade F, Strong Sell).

What is the price target of Telomir Pharmaceuticals, Inc. Common Stock (TELO)?

The analyst target price is $15.50, representing +1007.1% upside from the current price of $1.40.

Piotroski F-Score?

3/9 — weak financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

telomirpharma.com

Quick metrics

P/S ratio—

ROE-317.60%

Beta-0.73

50D MA$1.30

200D MA$1.42

Shares out0.07B

Float0.02B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

TELO vs LLY →TELO vs JNJ →TELO vs ABBV →Stock screener →